InspireMD receives approval to commercialize CGuardTM
Embolic prevention leader InspireMD Inc. received regulatory approval Monday to commercialize the CGuardTM Embolic Prevention System for the treatment of carotid artery disease in Argentina. The CGuard EPS prevents peri-procedural and late embolization by trapping potential emboli against the arterial wall. The global carotid stent market should grow 13 percent annually. Read More »